Your browser doesn't support javascript.
loading
Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil.
Chaisson, Lelia H; Saraceni, Valeria; Cohn, Silvia; Cavalcante, Solange C; Chaisson, Richard E; Durovni, Betina; Golub, Jonathan E.
Affiliation
  • Chaisson LH; Department of Medicine, University of Illinois at Chicago, Chicago, IL.
  • Saraceni V; Municipal Health Secretariat, Rio de Janeiro, Brazil.
  • Cohn S; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Cavalcante SC; Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
  • Chaisson RE; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Durovni B; Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and.
  • Golub JE; Municipal Health Secretariat, Rio de Janeiro, Brazil.
J Acquir Immune Defic Syndr ; 88(4): 329-332, 2021 12 01.
Article in En | MEDLINE | ID: mdl-34334739
OBJECTIVES: In Brazil, annual tuberculin skin tests (TSTs) are recommended for people living with HIV (PLWH) with CD4 >350, with tuberculosis preventive therapy provided on test conversion. We aimed to determine the yield of repeat TSTs for PLWH. DESIGN: Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT) to prevent tuberculosis (TB). METHODS: We analyzed data from newly registered PLWH with negative baseline TST results. We calculated the number of TST conversions after 1 and/or 2 years among patients eligible for follow-up TSTs, the proportion of converters initiating IPT, and incidence of TB/death. RESULTS: Among 1770 PLWH with a negative baseline TST, 679 (38%) were female and median age was 36 years (IQR 29-43). Eighty-six (5%) developed TB or died within 1 year. Among 1684 eligible for a follow-up 1-year TST, 582 (35%) were tested and 53 (9%) were positive. Forty-nine converters (92%) started IPT. Of 529 patients with a negative 1-year TST, 7 (1%) developed TB or died over the following year. Of 522 patients eligible for a 2-year TST, 158 (30%) were tested and 13 (8%) were positive. Ten converters (77%) started IPT. Of 1102 patients who did not receive a 1-year TST, 33 (3%) developed TB or died. Of the 1069 patients eligible for a 2-year TST, 259 (24%) were tested and 34 (13%) were positive. Thirty converters (88%) started IPT. CONCLUSIONS: In this cohort of PLWH in Brazil, TST conversion was high among those retested, but only 48% received a follow-up TST within 2 years.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Tuberculin Test / HIV Infections / Isoniazid / Antitubercular Agents Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Country/Region as subject: America do sul / Brasil Language: En Journal: J Acquir Immune Defic Syndr Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Tuberculin Test / HIV Infections / Isoniazid / Antitubercular Agents Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Country/Region as subject: America do sul / Brasil Language: En Journal: J Acquir Immune Defic Syndr Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document type: Article Country of publication: United States